BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 30098485)

  • 1. Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer - ESMO-MCBS scores.
    Broekman KE; Jalving M; van Tinteren H; Sessa C; Reyners AKL
    Cancer Treat Rev; 2018 Sep; 69():233-242. PubMed ID: 30098485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical benefit of systemic therapies for recurrent ovarian cancer-ESMO-MCBS scores.
    Broekman KE; van Kruchten M; van Tinteren H; Sessa C; Jalving M; Reyners AKL
    ESMO Open; 2021 Aug; 6(4):100229. PubMed ID: 34371383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit.
    Oosting SF; Barriuso J; Bottomley A; Galotti M; Gyawali B; Kiesewetter B; Latino NJ; Martinelli F; Pe M; Pentheroudakis G; Roitberg F; Vachon H; de Vries EGE; Piccart M; Cherny NI;
    Ann Oncol; 2023 Apr; 34(4):431-439. PubMed ID: 36549587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analyzing the clinical benefit of newer therapies for advanced or metastatic non-small-cell lung cancer: application of the ESMO-magnitude of clinical benefit scale v1.1.
    García-Fumero R; Fernández-López C; Calleja-Hernández MÁ; Expósito-Hernández J
    Acta Oncol; 2021 Sep; 60(9):1225-1232. PubMed ID: 34184595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna.
    Kiesewetter B; Raderer M; Prager GW; Fuereder T; Marosi C; Preusser M; Krainer M; Locker GJ; Brodowicz T; Zielinski CC
    ESMO Open; 2017; 2(3):e000166. PubMed ID: 28761758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1.
    Knapen DG; Cherny NI; Zygoura P; Latino NJ; Douillard JY; Dafni U; de Vries EGE; de Groot DJ
    ESMO Open; 2020 Sep; 5(5):e000681. PubMed ID: 32893188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score.
    Cherny NI; de Vries EGE; Dafni U; Garrett-Mayer E; McKernin SE; Piccart M; Latino NJ; Douillard JY; Schnipper LE; Somerfield MR; Bogaerts J; Karlis D; Zygoura P; Vervita K; Pentheroudakis G; Tabernero J; Zielinski C; Wollins DS; Schilsky RL
    J Clin Oncol; 2019 Feb; 37(4):336-349. PubMed ID: 30707056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework.
    de Hosson LD; van Veenendaal LM; Schuller Y; Zandee WT; de Herder WW; Tesselaar MET; Klümpen HJ; Walenkamp AME
    Ann Oncol; 2017 Dec; 28(12):3022-3027. PubMed ID: 29045525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for adjuvant radiotherapy in breast cancer.
    Sapir E; Cherny NI; Ennis RD; Smith BD; Smith GL; Marks LB; Corn BW
    ESMO Open; 2023 Jun; 8(3):101206. PubMed ID: 37236087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration.
    Molto C; Hwang TJ; Borrell M; Andres M; Gich I; Barnadas A; Amir E; Kesselheim AS; Tibau A
    Cancer; 2020 Oct; 126(19):4390-4399. PubMed ID: 32697362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five years of EMA-approved systemic cancer therapies for solid tumours-a comparison of two thresholds for meaningful clinical benefit.
    Grössmann N; Del Paggio JC; Wolf S; Sullivan R; Booth CM; Rosian K; Emprechtinger R; Wild C
    Eur J Cancer; 2017 Sep; 82():66-71. PubMed ID: 28648700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?
    Del Paggio JC; Azariah B; Sullivan R; Hopman WM; James FV; Roshni S; Tannock IF; Booth CM
    Ann Oncol; 2017 Jan; 28(1):157-162. PubMed ID: 27742650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.
    Tibau A; Molto C; Ocana A; Templeton AJ; Del Carpio LP; Del Paggio JC; Barnadas A; Booth CM; Amir E
    J Natl Cancer Inst; 2018 May; 110(5):486-492. PubMed ID: 29244173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring.
    Gyawali B; de Vries EGE; Dafni U; Amaral T; Barriuso J; Bogaerts J; Calles A; Curigliano G; Gomez-Roca C; Kiesewetter B; Oosting S; Passaro A; Pentheroudakis G; Piccart M; Roitberg F; Tabernero J; Tarazona N; Trapani D; Wester R; Zarkavelis G; Zielinski C; Zygoura P; Cherny NI
    ESMO Open; 2021 Jun; 6(3):100117. PubMed ID: 33887690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel.
    Hammerman A; Greenberg-Dotan S; Feldhamer I; Birnbaum Y; Cherny NI
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):119-122. PubMed ID: 28617621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
    van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
    Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical benefit of cancer drugs approved in Switzerland 2010-2019.
    Adam R; Tibau A; Molto Valiente C; Šeruga B; Ocaña A; Amir E; Templeton AJ
    PLoS One; 2022; 17(6):e0268545. PubMed ID: 35687539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epidermal growth factor receptor mutations.
    Giuliani J; Remo A; Bonetti A
    Expert Rev Pharmacoecon Outcomes Res; 2017 Feb; 17(1):5-8. PubMed ID: 27830967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer.
    Foote J; Secord AA; Liang M; Cohn DE; Jewell E; Havrilesky LJ
    J Oncol Pract; 2017 Dec; 13(12):e1030-e1039. PubMed ID: 29016225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
    Zhao XD; Zhang Q; Zhang Y
    Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.